Praxis Precision Medicines Provides Vormatrigine Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Raymond James sees a 'unique buying opportunity' in this stock
June 2, 2026 4:00 PM EDTRaymond James believes the recent selloff in one biopharmaceutical companys shares has created an attractive entry point for investors, arguing that disappointment surrounding the company's vormatrigine program does not alter its core investment thesis.
In a research note, Raymond James analyst Tiago Fauth reiterated a Strong Buy rating on Praxis Precision Medicines (NASDAQ: PRAX) and maintained a Strong Buy rating despite a failed... More
